Compare Flagstar Bank NA (FLG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Regeneron Pharmaceuticals Inc — how do they compare? Flagstar Bank NA trades at $15.4 (market cap $6.26B), while Regeneron Pharmaceuticals Inc trades at $677.52 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 11.1× Flagstar Bank NA's market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.57%). Which is the better fit depends on your goals.
| FLG | REGN | |
|---|---|---|
Market Cap | $6.26B | $69.66B |
Sector | Financials | Health |
52-Week High | $15.28 | $812.27 |
52-Week Low | $10.72 | $542.52 |
Dividend Yield | 0.27% | 0.57% |
Enterprise Value | — | $63.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $15.285, up 2.17% today, with a bullish technical signal from moving averages and a consensus analyst price target of $17.05. Recent earnings beat expectations in Q4 2025 and Q1 2026, though the company remains unprofitable on an annual basis with a net income margin of -2.71% in 2026. Positive developments include a proprietary technology transformation and a recent dividend declaration.
The outlook is cautiously optimistic, supported by analyst buy ratings and improving fundamentals, but risks include persistent negative profitability and high interest expenses. Upside is tied to continued execution on the turnaround and future earnings growth.
Regeneron (REGN) trades at $676.59, up 3.12% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.65% net income margin and $4.50B net income in 2025, supported by positive regulatory news including FDA acceptance of cemdisiran for gMG. Analyst consensus is strongly bullish with a $764.50 price target.
Outlook remains positive given earnings beats and regulatory tailwinds, but risks include dependence on key drugs and market volatility. The stock offers growth potential with a reasonable P/E of 16.22, though investors should monitor competitive pressures and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
